The 5 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 6.50, with a high estimate of 7.50 and a low estimate of 4.00. The median estimate represents a +96.97% increase from the last price of 3.30.
The current consensus among 6 polled investment analysts is to Buy stock in ZIOPHARM Oncology Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.08
Reporting Date Feb 25
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.